Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05375097 · ClinicalTrials.gov registry record
Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.
A clinical trial of Migraine, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 162
- Enrollment target
- 1
- Study location
NCT05375097: Completed study of Migraine, sponsored by Novartis Pharmaceuticals.
NCT05375097 is a study of Migraine that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 162 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05375097, a study of Migraine, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 162 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no patients were contacted for the study.
Primary Outcome
Sick leaves included migraine or head-ache related registered sick leave days at Terveystalo in the occupational healthcare cohort and controls.
Conditions Studied
Interventions
- OTHER Erenumab
Study Locations (1)
New Jersey
- Novartis Investigative Site - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2020-07-03 |
| Est. Completion | 2021-05-14 |
What the finished NCT05375097 record still lists
NCT05375097 is an observational study that tracks outcomes without assigning an intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Erenumab is the first listed.
NCT05375097 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05375097 about?
NCT05375097 is a clinical study titled "Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.". This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no patients were contacted for the study.
What is the current status of trial NCT05375097?
This trial is currently completed. The enrollment target is 162 participants. The study started on 2020-07-03. Estimated completion is 2021-05-14.
What conditions does trial NCT05375097 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05375097?
The interventions under investigation include: Erenumab (OTHER).
Who is sponsoring clinical trial NCT05375097?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05375097 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05375097's enrollment target sits among peer trials
162 46th of 102 higher than 57 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI